On 25 April 2023, the FDA granted approval for tofersen to treat amyotrophic lateral sclerosis (ALS) associated with mutations in the superoxide dismutase 1 (SOD1) gene [129]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.